ELUT Stock Forecast: Elutia, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Elutia, Inc. is $5. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 30 of 100 as at 21 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Elutia, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (73): The share price has been relatively steady.
Accruals (8): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
ELUT stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on ELUT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Of the 20 most recent actions, 2 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 10 Sept 2025 | Lake Street | Maintains | Buy | $8.00 → $6.00 |
| 9 May 2025 | Lake Street | Maintains | Buy | — |
| 7 Mar 2025 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 15 Nov 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 6 Sept 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 8 Aug 2024 | Cantor Fitzgerald | Maintains | Overweight | — |
| 21 June 2024 | Lake Street | Maintains | Buy | — |
| 20 June 2024 | Cantor Fitzgerald | Maintains | Overweight | — |
| 18 June 2024 | Cantor Fitzgerald | Maintains | Overweight | — |
| 10 May 2024 | Cantor Fitzgerald | Maintains | Overweight | — |
| 14 Nov 2023 | Cantor Fitzgerald | Maintains | Overweight | — |
| 28 Sept 2023 | Lake Street | Initiates | Buy | — |
| 26 Sept 2023 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 19 Sept 2023 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 15 Aug 2023 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 12 May 2023 | Cantor Fitzgerald | Maintains | Overweight | $12 → $10 |
| 16 Nov 2022 | Truist Securities | Maintains | Buy | $8.00 → $10 |
| 15 Nov 2022 | Piper Sandler | Maintains | Overweight | $9.00 → $11 |
| 4 Mar 2022 | Cowen & Co. | Maintains | Outperform | $15 → $13 |
| 2 Nov 2020 | Cantor Fitzgerald | Initiates | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for ELUT.
This page is one stock. Monday covers all of them.
ELUT appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
ELUT vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Elutia, Inc. returned +44.6% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
ELUT analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 2.9×
- Price / book
- 2.6×
- EV / EBITDA
- —
Cheaper than 37% of US stocks
Cheaper than 35% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- 59.6%
- Operating margin
- —
- Net margin
- —
Higher than 73% of US stocks
- Return on equity
- —
- Return on assets
- −36.5%
- Dividend yield
- —
Higher than 12% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Elutia, Inc. has a market value of $40.0M and an enterprise value of $23.9M.
Revenue in the twelve months to 30 June 2026: $12.1M. The latest quarter shrank 61.2% year on year.
Net income over the same four quarters: $51.8M, a 426.9% net margin.
Diluted earnings per share, trailing twelve months: $0.95.
Free cash flow in the twelve months to 30 June 2026: −$46.0M, after $2.0M of capital spending.
Elutia, Inc. employs 25 people — $485K of revenue per employee.
Data provided by Twelve Data
ELUT and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at ELUT’s peer groups, ranked by the model: healthcare stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Elutia, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about ELUT
What is the ELUT stock price forecast for 2026-2027?
The median 12-month analyst price target for Elutia, Inc. is $5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is ELUT stock a buy right now?
Of the 1 analyst covering Elutia, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Elutia, Inc. 30 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank ELUT?
As at 21 Nov 2026, Elutia, Inc. ranks 30 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Volatility (73 of 100).
Will ELUT stock go up?
No one can know that. What the data says: the median 12-month target from 1 analyst is $5, and Ticker Nerd's factor model ranks Elutia, Inc. 30 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the ELUT stock forecast for 2030?
No analyst covering Elutia, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ELUT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $5 over the next 12 months.
How has ELUT stock performed over the past year?
Elutia, Inc. returned +44.6% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Elutia, Inc. do?
Elutia Inc. is a commercial-stage biomedical company focused on drug-eluting biomatrix products used in surgical reconstruction and related medical applications. Elutia’s products are designed to improve how implantable medical devices and surrounding tissue interact, with use cases in areas such as device protection, women’s health, and cardiovascular care.
About Elutia, Inc.
Elutia Inc. is a commercial-stage biomedical company focused on drug-eluting biomatrix products used in surgical reconstruction and related medical applications. Elutia’s products are designed to improve how implantable medical devices and surrounding tissue interact, with use cases in areas such as device protection, women’s health, and cardiovascular care. The company offers biologic solutions intended for procedures involving implanted electronic devices, soft tissue repair, and regenerative support. Its portfolio serves healthcare providers working across specialized surgical settings where compatibility, tissue integration, and complication reduction are important. Elutia Inc. operates as a focused player in the regenerative medicine and biomaterials market, addressing needs in implant-based procedures and reconstructive care.
CEO Dr. C. Randal Mills Ph.D. · 25 employees · United States · https://elutia.com